Key points are not available for this paper at this time.
Two 25-μg doses of the mRNA-1273 vaccine were found to be safe in children 6 months to 5 years of age and elicited immune responses that were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.).
Anderson et al. (Wed,) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: